Back to Search
Start Over
Myelin-oligodendrocyte glycoprotein antibody-associated disease
- Source :
- Marignier, R, Hacohen, Y, Cobo-Calvo, A, Pröbstel, A-K, Aktas, O, Alexopoulos, H, Amato, M-P, Asgari, N, Banwell, B, Bennett, J, Brilot, F, Capobianco, M, Chitnis, T, Ciccarelli, O, Deiva, K, de Sèze, J R, Fujihara, K, Jacob, A, Kim, H J, Kleiter, I, Lassmann, H, Leite, M-I, Linington, C, Meinl, E, Palace, J, Paul, F, Petzold, A, Pittock, S, Reindl, M, Sato, D K, Selmaj, K, Siva, A, Stankoff, B, Tintore, M, Traboulsee, A, Waters, P, Waubant, E, Weinshenker, B, Derfuss, T, Vukusic, S & Hemmer, B 2021, ' Myelin-oligodendrocyte glycoprotein antibody-associated disease ', The Lancet Neurology, vol. 20, no. 9, pp. 762-772 . https://doi.org/10.1016/S1474-4422(21)00218-0, Marignier, R, Hacohen, Y, Cobo-Calvo, A, Pröbstel, A K, Aktas, O, Alexopoulos, H, Amato, M P, Asgari, N, Banwell, B, Bennett, J, Brilot, F, Capobianco, M, Chitnis, T, Ciccarelli, O, Deiva, K, De Sèze, J, Fujihara, K, Jacob, A, Kim, H J, Kleiter, I, Lassmann, H, Leite, M I, Linington, C, Meinl, E, Palace, J, Paul, F, Petzold, A, Pittock, S, Reindl, M, Sato, D K, Selmaj, K, Siva, A, Stankoff, B, Tintore, M, Traboulsee, A, Waters, P, Waubant, E, Weinshenker, B, Derfuss, T, Vukusic, S & Hemmer, B 2021, ' Myelin-oligodendrocyte glycoprotein antibody-associated disease ', The Lancet Neurology, vol. 20, no. 9, pp. 762-772 . https://doi.org/10.1016/S1474-4422(21)00218-0
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder that presents in both adults and children as CNS demyelination. Although there are clinical phenotypic overlaps between MOGAD, multiple sclerosis, and aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder (NMOSD) cumulative biological, clinical, and pathological evidence discriminates between these conditions. Patients should not be diagnosed with multiple sclerosis or NMOSD if they have anti-MOG antibodies in their serum. However, many questions related to the clinical characterisation of MOGAD and pathogenetic role of MOG antibodies are still unanswered. Furthermore, therapy is mainly based on standard protocols for aquaporin-4 antibody-associated NMOSD and multiple sclerosis, and more evidence is needed regarding how and when to treat patients with MOGAD.
- Subjects :
- Adult
Adolescent
CNS demyelination
Demyelinating Autoimmune Diseases, CNS
Disease
Myelin oligodendrocyte glycoprotein
Young Adult
medicine
Humans
Immunologic Factors
Spectrum disorder
Child
Pathological
Autoantibodies
Neuromyelitis optica
biology
business.industry
Multiple sclerosis
Middle Aged
medicine.disease
Immunology
biology.protein
Myelin-Oligodendrocyte Glycoprotein
Neurology (clinical)
Antibody
business
Biomarkers
Subjects
Details
- ISSN :
- 14744422
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- The Lancet Neurology
- Accession number :
- edsair.doi.dedup.....ce99a149910aa43ddde4dbbf5ef9759b